Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
22.90
-0.36 (-1.55%)
Nov 7, 2025, 4:00 PM EST - Market closed
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $730.00K in the quarter ending June 30, 2025, a decrease of -70.78%. This brings the company's revenue in the last twelve months to $5.79M, down -30.27% year-over-year. In the year 2024, Celldex Therapeutics had annual revenue of $7.02M with 1.99% growth.
Revenue (ttm)
$5.79M
Revenue Growth
-30.27%
P/S Ratio
262.49
Revenue / Employee
$31,129
Employees
186
Market Cap
1.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
| Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
| Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
| Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
| Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CLDX News
- 2 days ago - Celldex to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewsWire
- 2 months ago - Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track - Seeking Alpha
- 2 months ago - Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short - Benzinga
- 2 months ago - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 3 months ago - Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire